Population
In vitro model (platelets and whole blood)
Design
Preclinical
Authors
Loading...
NCX 4016's greater potency supports dual-mechanism exploration in animals; leaves open clinical translation and human outcome trials.
NCX 4016 and NCX 4215 demonstrate dual antiplatelet action in vitro via cyclo-oxygenase inhibition and nitric oxide release, with NCX 4016 being the more potent agent.
Lechi et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: